Educational Activities Archives

As the opioid use crisis continues to progress, communities across the country are now being faced with additional dangers such as the misuse of Xylazine, a powerful sedative commonly used for animals in the drug supply. Recent studies indicate these potent substances when used with opioids increase overdose risk and complicates treatment and long-term healthcare. Join us today as we discuss the history and context of Xylazine and opioid use as well as options for treatment and care.

Shared decision-making (SDM) involves a collaborative discussion between the patient and clinician about treatment options, advantages and disadvantages, and helps to identify the optimal treatment based on patient-specific needs and goals.and helps to identify the optimal treatment based on patient-specific needs and goals.

Join our 4-session online case-based learning collaborative series focused on treating opioid use disorder. Delve into best practices on Hospital Based Approaches to OUD and explore real-world cases provided by addiction experts, applying knowledge to practical situations. Each session is presented live online and spans 1.5 hours.

Fentanyl usage remains a critical public health concern in the US, contributing to alarming increases in overdose fatalities. Clinicians, patients, their families, and policymakers often find themselves uncertain about how to address this rapidly evolving landscape of illicit drug supply. This module aims to provide insights into extended-release injectable products and explore clinical strategies for effectively managing patients who use fentanyl.

Is it appropriate to prescribe buprenorphine monoproduct on a case-by-case basis for the treatment of Opioid Use Disorder for management of patients who experience adverse effects from buprenorphine/naloxone (bup/nx; Suboxone, Zubsolv)?

Transitioning from jails and prisons back into the community can be especially difficult for people with opioid use disorders (OUD). Research suggests that opioid use overdose increases dramatically within the first 30 days of citizens returning to the community. Further, individuals recently released from incarceration face a risk of opioid overdose ten times greater than the general public. During these transitions it is critical that people receive seamless and appropriate resources in order to prevent overdose and return to use. This proper transition can help lower health care costs, hospitalizations and emergency department visits, as well as decrease mortality and recidivism for justice-involved individuals, yet at this time only 13 states have sought Medicaid waivers to provide SUD services pre-release. Join us today as we explore how programs can successfully develop services to ensure returning citizens receive appropriate care to address OUD.